Journalists’ Award Supports Education About Renal Cancer

Raising awareness: Journalists’ Award supports education about renal cancer Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European "Advances in Renal Cancer" Award can be submitted until March 1, 2011 Leverkusen, February 16, 2011 - According to current estimates of the European Cancer Observatory (ECO), each year more than 71,000 patients are newly-diagnosed with kidney cancer all over Europe.(1) With a mortality rate of over 40 percent, renal cell carcinoma is the most dangerous type of all urological tumors. That is why educating the public about the disease and promoting early detection is of pivotal importance. Especially, since early diagnosis improves the chances of recovery and can help to save the life of patients with renal cancer. The disease is especially insidious, because typical symptoms often appear at a very late stage and the tumor is, in many cases, only discovered by chance. To support and promote journalistic reporting focusing on renal cell carcinoma and current medical developments, Bayer HealthCare and the Kidney Cancer Association (KCA) have announced the European "Advances in Renal Cancer" Journalists’ Award 2011. For the third time, the prize honors publications, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print m...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Publication date: Available online 12 October 2019Source: European UrologyAuthor(s): Karlijn de Joode, Astrid A.M. van der Veldt
Source: European Urology - Category: Urology & Nephrology Source Type: research
In conclusion, miR-877 may play an antitumor role in cervical cancer by directly targeting MACC1, which suggests that this miRNA may be a promising therapeutic target for the treatment of patients with such an aggressive gynecological cancer. PMID: 31602243 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non–TFEB-altered contr...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
This study aimed to evaluate the utility of the AACI for predicting long-term survival in patients with surgically treated non-metastatic clear cell RCC (ccRCC).MethodsData from 698 patients with non-metastatic ccRCC who underwent radical or partial nephrectomy as primary therapy from a multi-institutional Korean collaboration between 1988 and 2015 were retrospectively analyzed. Clinicopathological variables and survival outcomes of those with AACI scores  ≤ 3 (n = 324), 4–5 (n = 292), and ≥ 6 (n = 82) were compared.ResultsPatients with a hig...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewTo critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC).Recent FindingsRadioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an in...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
Abstract AIM: To provide a comprehensive analysis of the outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for renal cell carcinoma (RCC) in older patients. METHODS: The RESURGE project is a multi-institutional dataset including 24 institutions worldwide collecting data of patients older than 75 years old who underwent RN or PN. RESULTS: Among three already published studies, RN patients were older (p 
Source: Aging Clinical and Experimental Research - Category: Geriatrics Authors: Tags: Aging Clin Exp Res Source Type: research
In this study, we collected microarray profiles of 72 ccRCCs and matched normal samples to identify differentially expressed genes (DEGs). Then a weighted gene co-expression network analysis (WGCNA) was conducted to identify co-expressed gene modules. By relating all co-expressed modules to clinical features, we found that the brown module and Fuhrman grade had the highest correlation (r = −0.8, p = 1e-09). Thus, the brown module was regarded as a clinically significant module and subsequently analyzed. Functional annotation showed that the brown module focused on metabolism-related biological processes and pathways,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Pathological complete response with nivolumab in metastatic renal cell carcinoma is rare. This case further highlights the potentially predictive role of immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma and raises questions concerning the role of nephrectomy after immune checkpoint inhibitor therapy. Further studies are needed to better identify predictive factors for treatment response to immunotherapy in metastatic renal cell carcinoma, and to better understand the role of nephrectomy after nivolumab treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study analyzed the relationship between organ involvement and survival of VHL patients. This may help guide future genetic counseling and clinical decision-making.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: TSR, locoregional recurrence, tumor bed recurrence, and contralateral tumor development are observed patterns of RCC recurrence after RPN. Recurrence was seen in up to 72 months. RPN provides great cancer control and high cure rate when utilized to treat RCC presenting as SRM.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Education | Health | Health Management | Kidney Cancer | Nutrition | Renal Cell Carcinoma | Universities & Medical Training | Urology & Nephrology | Websites